Bevacizumab Against Recurrent Retinal Detachment
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular, Psychiatric |
| Therapuetic Areas: | Ophthalmology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/7/2019 |
| Start Date: | January 21, 2015 |
| End Date: | April 2020 |
The investigators hypothesize that bevacizumab instilled into the vitreous after primary
retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and
subsequent retinal re-detachment.
retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and
subsequent retinal re-detachment.
Inclusion Criteria:
- Age ≥ 18 years
- Eyes with rhegmatogenous retinal detachment
Exclusion Criteria:
- Presence of PVR
- Need for a procedure other than primary PPV such as a scleral buckle with or without
PPV, laser retinopexy, or pneumatic retinopexy.
- Recent intravitreal injection of an anti-VEGF agent less than 3 months prior
- Secondary retinal detachment repair
- Use of silicone oil as tamponade agent
- Patients less than 18 years of age
- Pregnancy
- Known allergy or contraindication to intravitreal bevacizumab
We found this trial at
1
site
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Click here to add this to my saved trials
